M
Michael L. Terrin
Researcher at University of Maryland, Baltimore
Publications - 139
Citations - 17598
Michael L. Terrin is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Randomized controlled trial & Myocardial infarction. The author has an hindex of 49, co-authored 132 publications receiving 16139 citations. Previous affiliations of Michael L. Terrin include Mount Sinai St. Luke's and Mount Sinai Roosevelt & University of Cincinnati.
Papers
More filters
Journal ArticleDOI
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
Samuel Charache,Michael L. Terrin,Richard D. Moore,George J. Dover,Franca B. Barton,Susan V. Eckert,Robert P. McMahon,Duane Bonds +7 more
TL;DR: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year and Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect.
Journal ArticleDOI
Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis
Robert P. Baughman,Alvin S. Teirstein,Marc A. Judson,Milton D. Rossman,Henry Yeager,Eddy A. Bresnitz,Louis DePalo,Gary M. Hunninghake,Michael C. Iannuzzi,Carol J. Johns,Geoffrey McLennan,David R. Moller,Lee S. Newman,David L. Rabin,Cecile S. Rose,Benjamin A. Rybicki,Steven E. Weinberger,Michael L. Terrin,Genell L. Knatterud,Reuben Cherniak +19 more
TL;DR: It is concluded that the initial presentation of sarcoidosis is related to sex, race, and age.
Journal ArticleDOI
Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery
Jeffrey L. Carson,Michael L. Terrin,Helaine Noveck,David W. Sanders,Bernard R. Chaitman,George G. Rhoads,George J. Nemo,Karen Dragert,Lauren A Beaupre,Kevin A. Hildebrand,William Macaulay,Courtland Lewis,Donald Richard Cook,Gwendolyn Dobbin,Khwaja J. Zakriya,Fred S. Apple,Rebecca A. Horney,Jay Magaziner +17 more
TL;DR: A liberal transfusion strategy, as compared with a restrictive strategy, did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk.
Journal ArticleDOI
The clinical course of pulmonary embolism.
Jeffrey L. Carson,Mark A. Kelley,Amy Duff,John G. Weg,William J. Fulkerson,Harold I. Palevsky,J. Sanford Schwartz,B. Taylor Thompson,John Popovich,Thomas E. Hobbins,Margaret A. Spera,Abass Alavi,Michael L. Terrin +12 more
TL;DR: When properly diagnosed and treated, clinically apparent pulmonary embolism was an uncommon cause of death, and it recurred in only a small minority of patients.
Journal ArticleDOI
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
Martin H. Steinberg,Martin H. Steinberg,Franca B. Barton,Oswaldo Castro,Charles H. Pegelow,Samir K. Ballas,Abdullah Kutlar,Eugene P. Orringer,Rita Bellevue,Nancy F. Olivieri,James R. Eckman,Mala Varma,G. Ramirez,Brian Adler,Wally R. Smith,Timothy M. Carlos,Kenneth I. Ataga,Laura DeCastro,Carolyn Bigelow,Yogen Saunthararajah,Margaret Telfer,Elliott Vichinsky,Susan Claster,Susan Shurin,Kenneth Bridges,Myron A. Waclawiw,Duane Bonds,Michael L. Terrin +27 more
TL;DR: In a long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Patients with Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine whether hydroxyuraxurea attenuates mortality in Patients With SCA as discussed by the authors.